Positron emission tomography/computed tomography is a hybrid nuclear medicine imaging technique that helps radiologists spot abnormal metabolic activity. PET/CT is commonly used to diagnose cancers, heart diseases and certain brain disorders, among other conditions.
The San Francisco-based company says the updates will accelerate radiology workflows by removing administrative burdens and freeing up radiologists to spend more time reviewing imaging exams instead.
The method targets cancer stem cells, which are highly tumorigenic and known to play a significant role in relapse, cancer spread and treatment resistance.
The agent “exhibits powerful tumor delineation” in challenging cases of determining cancer subtypes, and could potentially lead to more personalized, effective treatment strategies.
The deal will create a Therapy Command Center to support the study and use of theranostics across Massachusetts General Hospital and its affiliated centers in bordering states.
The designation was awarded to a research team from China, who analyzed the efficacy of a novel radiotracer developed to target expression of the PD-L1 protein in suspected head and neck cancers.